The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
5-year survival outcomes after perioperative pembrolizumab (pembro) in patients with human papillomavirus (HPV)-unrelated, locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multi-center, two-cohort, phase 2 trial.
 
Edward Sim
No Relationships to Disclose
 
Ann Marie Egloff
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); GE Healthcare (I)
Research Funding - Daiichi Sankyo
 
Tanujit Dey
No Relationships to Disclose
 
Rebecca Chernock
Leadership - Merck Steering Committee
(OPTIONAL) Uncompensated Relationships - Caris's Precision Oncology Alliance
 
Robert Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - ALX Oncology; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Eisai; EMD Serono; Genmab; Genzyme; GlaxoSmithKline; Johnson & Johnson/Janssen; Merck; PDS Biotechnology; Scholar Rock
Research Funding - AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Merus (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; ISA Pharmaceuticals; Nanobiotix
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; Elevar Therapeutics; Grey Wolf Therapeutics; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; PDS Biotechnology; Remix Therapeutics; Replimune; Surface Oncology
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); Kura Oncology (Inst); Regeneron (Inst); Secura Bio (Inst)
 
Jonathan Schoenfeld
Employment - Brigham and Women's Hospital
Stock and Other Ownership Interests - Immunitas; Intragel
Consulting or Advisory Role - EMD Serono; Immunitas; Merck KGaA
Research Funding - Bristol-Myers Squibb; EMD Serono/Merck; Merck; Regeneron; Siemens
Patents, Royalties, Other Intellectual Property - MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF; Nanobody bioconjugation for immune receptor targeting
Expert Testimony - Burns and White
 
Laura Goguen
No Relationships to Disclose
 
Donald Annino
No Relationships to Disclose
 
Vickie Jo
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
 
Peter Oppelt
Research Funding - Enzychem Lifesciences (Inst); HiFiBiO Therapeutics (Inst); Merck (Inst)
 
Patrik Pipkorn
No Relationships to Disclose
 
Ryan Jackson
Honoraria - Intuitive Surgical
 
Sidharth Puram
No Relationships to Disclose
 
Jose Zevallos
Employment - University of Pittsburgh Medical Center
Stock and Other Ownership Interests - Droplet Biosciences; Echogenesis Therapeutics; Vine Medical
Consulting or Advisory Role - Johnson & Johnson/Janssen; Merck
Patents, Royalties, Other Intellectual Property - Multiple patents pending related to Droplet Biosciences and use of surgical drain fluid for diagnostics; Patient on device for early detection of HPV+ oropharyngeal cancer
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Jessica Ley
Travel, Accommodations, Expenses - NATCO Pharma (Inst)
 
Luc Morris
Patents, Royalties, Other Intellectual Property - I am an inventor on IP owned by Memorial Sloan Kettering Cancer Center and licensed to PGDx
 
Lara Dunn
Consulting or Advisory Role - Regeneron
Research Funding - Imvaq Therapeutics; Regeneron; Replimune; Seagan
 
Ravindra Uppaluri
Consulting or Advisory Role - Daichi-Sankyo; Merck; Regeneron
Research Funding - Daichi-Sankyo; Merck
Patents, Royalties, Other Intellectual Property - Washington University licenses mouse oral cancer cell lines made by my lab. I receive royalties from Washington University from these agreements.
 
Douglas Adkins
Consulting or Advisory Role - Adlai Nortye; Boehringer Ingelheim; CUE Biopharma; Exelixis; Genmab/Seattle Genetics; Immunitas; InhibRx; Kura Oncology; Merck; Merck KGaA; Merus; NATCO Pharma; Purple Biotech; Regeneron; Sanofi; Seagen; TargImmune Therapeutics
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - NATCO Pharma (Inst)